PP-C8

CAT: 0804-HY-144691-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-144691-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PP-C8 is a potent and selective PROTAC CDK12-Cyclin K degrader. PP-C8 induces CDK12-Cyclin K degradation with DC50s of 416 and 412 nM for CDK12 and Cyclin K, respectively. PP-C8 demonstrates profound synergistic antiproliferative effects with PARP inhibitor in triple-negative breast cancer (TNBC) [1].
CAS Number
[3032108-74-7]
UNSPSC
12352005
Target
CDK; PROTACs
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pp-c8.html
Purity
99.99
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CC(N1C=NC2=C1N=C(N=C2NCC3=NC4=CC(F)=C(C=C4N3)NCCCCCCCCNC(COC5=C6C(N(C(C6=CC=C5)=O)C7CCC(NC7=O)=O)=O)=O)N8CCOCC8)C
Molecular Formula
C43H51FN12O7
Molecular Weight
866.94
References & Citations
[1]Tian Niu, et al. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor. Eur J Med Chem. 2022 Jan 15;228:114012.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-170734Cannabidiol-C8
HY-108391-01C8-Ceramide
HY-119312C8 Dihydroceramide
HY-175410DOPE-C8
HY-144008C8 PEG-Ceramide
HY-144008AC8 PEG5000 Ceramide
HY-144008B-01C8 PEG750 Ceramide
HY-13786O6BTG-C8-αGlu
HY-130952-01Thalidomide-O-C8-COOH
HY-173380C8 DG PEG 2000

Alternative Products

CatalogName
BA3823-5.1PP-C8
A24005-1PP-C8 1mg
A24005-5PP-C8 5mg
A24005-50PP-C8 50mg
A24005-10PP-C8 10mg
pro-2695C8
M10530-01J8-C8
MF-0000776C8-Ceramide
MF-0043934C8 Dihydroceramide
C31006-01C8 β Antibody

Popular Products